Beyond Glycaemic Control | Diabetes on the Net

For healthcare professionals only

Getting the timing right: when to consider a GLP-1 receptor agonist in type 2 diabetes

Thursday 2 July 2020
at 1.00pm and 7.00pm
This promotional meeting is organised and funded by Novo Nordisk. For healthcare professionals only. Promotional product information will be discussed. Marketing and organisational support has been provided by OmniaMed Communications.

Examining the use of glucagon-like peptide-1
(GLP-1) receptor agonists in clinical practice

Join us for a live webinar in which Dr Amar Puttanna, a Consultant Diabetologist based in Sutton Coldfield, will look at the burden of type 2 diabetes, and the impact of the updated ADA/EASD guidance1 on the chronology of initiating GLP-receptor agonists in this condition.

Dr Puttanna will discuss clinical trial data for a GLP-1 receptor agonist versus basal insulin and suggest the right time for initiating GLP-1 receptor agonists. After the presentation, join Dr Puttanna for a live Q&A session.

Reference 1. Buse JB et al (2020) Diabetes Care 43:487–93

This live webinar will cover topical issues around

  • The burden of type 2 diabetes
  • The role of treatment guidelines in the management of type 2 diabetes
  • Injectable treatment initiation: GLP-1 receptor agonist or basal insulin
  • The clinical trial data comparing semaglutide and basal insulin

When will this webinar
take place

  • Thursday 2 July 2020
  • The webinar will be broadcast at 1.00pm and 7.00pm

This webinar
will also include?

  • Live Q&A session with expert speaker, Dr Amar Puttanna, ready to answer your questions

Guest webinar

Dr Amar Puttanna

Amar Puttanna is a Diabetes and Endocrine Consultant in the West Midlands. He is particularly interested in education, having won teaching awards from the University of Birmingham and the Royal College of Physicians of Edinburgh and currently sits on the MRCP Part 1 examining board.

Dr Puttana contributes to writing guidelines and patient information for older individuals, including those published by the Joint British Diabetes Societies and TREND-UK, as well as local guidelines. He has also served on a NICE scoping board as diabetes specialist with interest in cardiovascular disease and sits on the editorial board for the British Journal of Cardiology. His interests are in cardiovascular disease, diabetes management in older adults and cognitive impairment.

Register now for our upcoming event!

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Live scheduled event

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.